Nyxoah (NASDAQ:NYXH) Price Target Lowered to $19.00 at Stifel Nicolaus

Nyxoah (NASDAQ:NYXH) had its price objective dropped by equities research analysts at Stifel Nicolaus from $27.00 to $19.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 126.73% from the company’s current price.

A number of other research analysts have also recently issued reports on the company. Oppenheimer decreased their target price on Nyxoah from $20.00 to $15.00 and set an “outperform” rating for the company in a research note on Wednesday, May 15th. Piper Sandler boosted their target price on Nyxoah from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Cantor Fitzgerald decreased their target price on Nyxoah from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, May 15th. Finally, HC Wainwright decreased their target price on Nyxoah from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Nyxoah has an average rating of “Moderate Buy” and a consensus price target of $17.80.

Nyxoah Price Performance

Shares of Nyxoah stock opened at $8.38 on Monday. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00. The business has a fifty day simple moving average of $9.33 and a 200 day simple moving average of $9.77.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) EPS for the quarter, hitting analysts’ consensus estimates of ($0.45). Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. The business had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.20 million. Sell-side analysts predict that Nyxoah will post -1.69 EPS for the current fiscal year.

Institutional Trading of Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 50,699 shares of the company’s stock, valued at approximately $684,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.